Review
Public, Environmental & Occupational Health
Laura Puzniak, Ryan Dillon, Thomas Palmer, Hannah Collings, Ashley Enstone
Summary: The review shows that Ceftolozane/tazobactam (C/T) is effective in clinical practice for gram-negative infections, even in seriously ill patients with resistant pathogens. Comparative studies suggest that C/T is a successful alternative to standard of care (SoC), with similar or better outcomes compared to other regimens.
ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL
(2021)
Article
Immunology
Lucinda J. Van Anglen, Claudia P. Schroeder, Kimberly A. Couch
Summary: This study reports the utilization and outcomes of Ceftolozane/tazobactam (C/T) use in the outpatient setting. C/T was successfully used to treat various serious infections, with a high prevalence of resistant pathogens and comorbidities among patients.
OPEN FORUM INFECTIOUS DISEASES
(2023)
Article
Infectious Diseases
Woraphot Tantisiriwat, Jirawat Buppanharun, Chatchai Ekpanyaskul, Kwanchai Onruang, Thitiya Yungyuen, Pattarachai Kiratisin, Somchai Santiwatanakul
Summary: This study aimed to assess the in vitro activity of ceftolozane-tazobactam (C-T) against resistant Pseudomonas aeruginosa (PA) and investigate the resistant genes in PA strains that were resistant to C-T.
Article
Microbiology
Lina Rivas, Manuel Alcalde-Rico, Jose R. W. Martinez, Maria Victoria Moreno, Pamela Rojas, Aniela Wozniak, Patricia Garcia, Jorge Olivares-Pacheco, William R. Miller, Cesar A. Arias, Ayesha Khan, Jose M. Munita
Summary: This study evaluated the performance of different antimicrobial susceptibility testing methods in non-carbapenemase producing-carbapenem-resistant Pseudomonas aeruginosa, revealing a significant decrease in performance when testing isolates resistant to all beta-lactams.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Review
Infectious Diseases
Laura Puzniak, Ryan Dillon, Thomas Palmer, Hannah Collings, Ashley Enstone
Summary: Ceftolozane/tazobactam (C/T) has shown good clinical and microbiological success rates in the real-world clinical practice for treating Gram-negative respiratory tract infections, despite the challenge of multidrug-resistant pathogens.
INFECTIOUS DISEASES AND THERAPY
(2021)
Review
Biology
Luca Gregorio Giaccari, Maria Caterina Pace, Maria Beatrice Passavanti, Francesca Gargano, Caterina Aurilio, Pasquale Sansone
Summary: Ceftolozane/tazobactam (C/T) may be a valid therapeutic option for treating multidrug-resistant Pseudomonas aeruginosa infections, with high clinical success rates and good tolerability, making it feasible to use in various comorbidities.
Article
Pharmacology & Pharmacy
Mar Ronda, Sandra Perez-Recio, Monica Gonzalez Laguna, Maria de la Fe Tubau Quintano, Josep Llop Talaveron, Laura Soldevila-Boixader, Jordi Carratala, Guillermo Cuervo, Ariadna Padulles
Summary: This study evaluated the real-world clinical efficacy of ceftolozane/tazobactam (C/T) in difficult-to-treat infections caused by multi-drug resistant Gram-negative microorganisms. The results showed that C/T had a favourable clinical profile in treating these infections.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
(2022)
Article
Oncology
Madison Koons, Jessie R. Signorelli, Chris Bell, Brenna Rowen
Summary: This study evaluates the impact of pharmacist's prospective review of luspatercept doses on efficacy. The results show a higher percentage of off-label doses in a center without pharmacist's prospective review, and the center with pharmacist's prospective review has a higher percentage of patients achieving transfusion independence.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2023)
Article
Immunology
Ibrahim Bitar, Tamara Salloum, Georgi Merhi, Jaroslav Hrabak, George F. Araj, Sima Tokajian
Summary: This study investigated the resistance patterns and beta-lactamases associated with ceftolozane/tazobactam (C/T) resistance in multi-drug resistant Pseudomonas aeruginosa clinical isolates. Whole-genome sequencing revealed the presence of acquired OXA beta-lactamases and metallo-beta-lactamases as the main drivers of C/T resistance.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Article
Infectious Diseases
Bernard Castan, Brune Akrich, Laurie Levy-Bachelot, Anna Amode, Anne Berthelot, Carole Mackosso, Lucie Mathis, Joy Mootien, Raymond Ruimy, Fabrice Ruiz, Jean-Francois Timsit, D. Boutoille
Summary: This study investigated the real-world clinical use of C/T in France and found that most patients had risk factors for MDR bacteria infections, with a majority being critically ill. The results indicated that C/T was frequently prescribed for P. aeruginosa infections, and most patients showed positive outcomes with a relatively low mortality rate.
INFECTIOUS DISEASES NOW
(2021)
Article
Oncology
Vivek A. Upadhyay, Bruce E. Johnson, Adam B. Landman, Michael J. Hassett
Summary: The purpose of this study was to measure the use of off-label molecularly targeted therapy and describe the clinical situations in which it is used. The study found that off-label use of targeted therapy was uncommon in a large cohort of solid tumor patients. However, a notable proportion of patients had treatment durations of 6 months or longer and survivals of 2 years or more.
JCO PRECISION ONCOLOGY
(2022)
Article
Infectious Diseases
George G. Zhanel, Rita Dhami, Melanie Baxter, Justin Kosar, Carlos Cervera, Neal Irfan, Rosemary Zvonar, Sergio Borgia, Jean-Francois Tessier, Gordon Dow, Robert Ariano, Maxime Dube, Michel Savoie, Matteo Bassetti, Andrew Walkty, James A. Karlowsky
Summary: The use of Ceftolozane/tazobactam in Canada for severe infections caused by multidrug-resistant P. aeruginosa shows relatively high cure rates and good safety profile when used in combination with other antimicrobials, as reported in the national registry.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2021)
Article
Oncology
Rim Turfa, Tala Alawabdeh, Ayman Naser, Yazan Alamro, Moath Albliwi, Sama Almasri, Abdullah Al Qazakzeh, Mohammad Abu Shattal, Ali Dabous, Rula Amarin
Summary: This study compares the real-world outcomes of standard treatment for locally advanced rectal cancer (CRT) and total neoadjuvant treatment (TNT). The results show that TNT can achieve better pathological complete remission (pCR), lower recurrence rates, and improved 3-year event-free survival (EFS) and overall survival (OS) compared to CRT.
FRONTIERS IN ONCOLOGY
(2023)
Article
Infectious Diseases
Francesco Venuti, Alberto Gaviraghi, Amedeo De Nicolo, Giacomo Stroffolini, Bianca Maria Longo, Alessia Di Vincenzo, Fabio Antonino Ranzani, Matilde Quaranta, Francesca Romano, Eleonora Catellani, Carlotta Marchiaro, Giacoma Cinnirella, Antonio D'Avolio, Stefano Bonora, Andrea Calcagno
Summary: This study retrospectively included three adult outpatients receiving continuous infusion of C/T to treat MDR-P. aeruginosa infections. The results showed that this treatment method can effectively resolve clinical symptoms, achieve PK/PD targets, and contribute to infection control strategies.
Article
Engineering, Electrical & Electronic
Jose A. Guzman, Brendan T. Morris, Felipe Nunez
Summary: Mobility and transportation services in large-scale cities are affected by traffic congestion, which can be mitigated through preventive measures based on traffic predictions. Deep learning models have excelled in tackling the traffic prediction problem using data-driven approaches. However, real-time implementation of these techniques is still under development. This study presents the implementation of a real-time traffic prediction application in Las Vegas, USA, demonstrating the feasibility of real-time traffic prediction and the importance of periodic retraining to maintain prediction accuracy.
IEEE INTELLIGENT TRANSPORTATION SYSTEMS MAGAZINE
(2023)
